Joe Copia's daytrades/investments and thoughts Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Phatt Jake who wrote (10720)	12/23/1998 10:59:00 AM
From: T2001	Read Replies (1) of 25711

APPI at .024 all buys December 23, 1998 10:15 Advanced Plant Pharmaceuticals Inc. Announces Exclusive Distribution Agreement for Patented Cholesterol Lowering Agent Lo-Chol and New Line of Proprietary Whole Plant Standardized Pharmaceutical Grade Products NEW YORK, Dec. 23 /PRNewswire/ -- Advanced Plant Pharmaceuticals Inc. (OTC Bulletin Board: APPI) announced today that they have signed an agreement with Klien Associates of Israel. The provisions of the agreement call for the exclusive distribution of Lo-Chol and APPI's new product line of various Pharmaceutical Grade Nutritional products by Klien Associates throughout the Country of Israel. Pursuant to the agreement Klien Associates has made an initial purchase order of Lo-Chol and will have an exclusive 3 month trial distribution right to distribute Lo-Chol in the territory of Israel. Upon the completion of the trial distribution period Klien Associates will have the right of first refusal for the distribution of Lo-Chol and APPI's new line of various Pharmaceutical Grade Nutritional products exclusively in Israel based on minimum purchases and conditions that will be set forth in a new agreement. The company expects to announce further agreements in the near future. APPI is a company that develops innovative plant formulations and technology for clinical application. APPI has met FDA nutritional specifications for the marketing of its Lo-Chol in the USA, and has received the first IND from the FDA for a whole plant pharmaceutical which has potential as an immunomodulater in the treatment of patients infected with HIV, the virus that causes AIDS. APPI's Whole Plant Pharmaceutical Grade Process is trade secret and patent pending. Utilization of the APPI process converts a whole plant into the best standardized pharmaceutical grade product. This press release contains forward-looking statements. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. SOURCE Advanced Plant Pharmaceuticals Inc. /CONTACT: Barry Clare of Advanced Plant Pharmaceuticals Inc., 212-402-7878; or Michael Klien of Klien Associates, 641-5112/ /Web site: advancedplantpharm.com (APPI)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next